Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $6.0000 (1.01%) ($5.7300 - $6.0700) on Tue. Oct. 30, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.28% (three month average) | RSI | 4 | Latest Price | $6.0000(1.01%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -3.3% a day on average for past five trading days. | Weekly Trend | ADAP declines -28.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(18%) GDXJ(13%) ICLN(12%) JETS(12%) TAN(11%) | Factors Impacting ADAP price | ADAP will decline at least -2.64% in a week (0% probabilities). VIXM(-10%) XLP(-8%) VXX(-6%) XLV(-4%) TBT(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.64% (StdDev 5.28%) | Hourly BBV | 0 () | Intraday Trend | 1.9% | | | |
|
1 - 5 Day Possible Target | $-35.15(-685.83%) | Resistance Level | $10.27 | 5 Day Moving Average | $6.24(-3.85%) | 10 Day Moving Average | $7.77(-22.78%) | 20 Day Moving Average | $10.27(-41.58%) | To recent high | -57.6% | To recent low | 1% | Market Cap | $928m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |